Leap Therapeutics (LPTX) PT Raised to $5 at Piper Sandler Following Positive Data at ESMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leap Therapeutics (LPTX) Prices $90M Share and Warrant Offering at $2.85/sh
September 22, 2021 8:31 AM EDTLeap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $2.849 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Leap from this offering are expected to be approximately $90 million, before deducting... More
Leap Therapeutics (LPTX) Climbs 58%
September 16, 2021 6:08 AM EDTLeap Therapeutics (NASDAQ: LPTX) Climbs 58%
Earlier Leap Therapeutics (LPTX) Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab... MoreLeap Therapeutics (LPTX) Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab
September 16, 2021 5:55 AM EDTLeap Therapeutics, Inc. (Nasdaq: LPTX) today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress.... More
